FR23C1036I2 - ANTIBODIES THAT BIND TO IL-23 - Google Patents

ANTIBODIES THAT BIND TO IL-23

Info

Publication number: FR23C1036I2
Authority: FR; France
Prior art keywords: antibodies; bind
Prior art date: 2013-03-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR23C1036C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-08

Filing date

2023-10-13

Publication date

2024-10-04

2023-10-13 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2023-12-08 Publication of FR23C1036I1 publication Critical patent/FR23C1036I1/en

2024-10-04 Application granted granted Critical

2024-10-04 Publication of FR23C1036I2 publication Critical patent/FR23C1036I2/en

Status Active legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Obesity (AREA)
Hematology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Transplantation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

FR23C1036C 2013-03-08 2023-10-13 ANTIBODIES THAT BIND TO IL-23 Active FR23C1036I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361774732P	2013-03-08	2013-03-08
PCT/US2014/020064 WO2014137962A1 (en)	2013-03-08	2014-03-04	Antibodies that bind il-23

Publications (2)

Publication Number	Publication Date
FR23C1036I1 FR23C1036I1 (en)	2023-12-08
FR23C1036I2 true FR23C1036I2 (en)	2024-10-04

Family

ID=51488096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR23C1036C Active FR23C1036I2 (en)	2013-03-08	2023-10-13	ANTIBODIES THAT BIND TO IL-23

Country Status (40)

Country	Link
US (3)	US9023358B2 (en)
EP (3)	EP2964258B1 (en)
JP (1)	JP6096938B2 (en)
KR (2)	KR20170103037A (en)
CN (1)	CN105307681B (en)
AP (1)	AP2015008708A0 (en)
AR (1)	AR094877A1 (en)
AU (1)	AU2014226094C1 (en)
BR (1)	BR112015019611B1 (en)
CA (1)	CA2901462C (en)
CL (1)	CL2015002388A1 (en)
CY (2)	CY1123589T1 (en)
DK (1)	DK2964258T3 (en)
EA (1)	EA031524B1 (en)
EC (1)	ECSP15038626A (en)
ES (1)	ES2822662T3 (en)
FI (1)	FIC20230030I1 (en)
FR (1)	FR23C1036I2 (en)
HR (1)	HRP20201633T1 (en)
HU (2)	HUE051357T2 (en)
IL (2)	IL240731B (en)
JO (1)	JOP20140049B1 (en)
LT (2)	LT2964258T (en)
MA (1)	MA38382A1 (en)
MX (1)	MX370396B (en)
MY (1)	MY171226A (en)
NL (1)	NL301247I2 (en)
NO (1)	NO2023037I1 (en)
PE (1)	PE20151529A1 (en)
PH (1)	PH12015501994B1 (en)
PL (1)	PL2964258T3 (en)
PT (1)	PT2964258T (en)
RS (1)	RS60928B1 (en)
SG (1)	SG11201507176VA (en)
SI (1)	SI2964258T1 (en)
TN (1)	TN2015000348A1 (en)
TW (1)	TWI636063B (en)
UA (1)	UA123198C2 (en)
WO (1)	WO2014137962A1 (en)
ZA (1)	ZA201505285B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR102417A1 (en) *	2014-11-05	2017-03-01	Lilly Co Eli	ANTI-TNF- / ANTI-IL-23 BIESPECTIFIC ANTIBODIES
US20180291093A1 (en) *	2015-10-30	2018-10-11	Eli Lilly And Company	Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
AR111845A1 (en)	2017-05-03	2019-08-28	Lilly Co Eli	ANTI-CGRP / ANTI-IL-23 BIESPECTIFIC ANTIBODIES AND USES OF THE SAME
TWI744617B (en)	2018-03-30	2021-11-01	美商美國禮來大藥廠	Methods of treating ulcerative colitis
TWI725532B (en)	2018-09-11	2021-04-21	美商美國禮來大藥廠	Methods of treating psoriasis
TWI850365B (en)	2019-04-22	2024-08-01	美商美國禮來大藥廠	Methods of treating crohn's disease
KR20220054689A (en)	2019-10-15	2022-05-03	일라이 릴리 앤드 캄파니	Recombinantly engineered, lipase/esterase-deficient mammalian cell line
CA3164996A1 (en)	2019-12-20	2021-06-14	Novarock Biotherapeutics, Ltd.	Anti-interleukin-23 p19 antibodies and methods of use thereof
CN112807428B (en) *	2020-06-12	2024-08-27	江苏荃信生物医药股份有限公司	Pharmaceutical composition comprising anti-human interleukin 23 monoclonal antibody
WO2022041390A1 (en) *	2020-08-28	2022-03-03	江苏荃信生物医药股份有限公司	Low viscosity liquid formulation comprising high concentration anti-human interleukin 23 monoclonal antibody, and preparation method therefor
AR123477A1 (en)	2020-09-10	2022-12-07	Lilly Co Eli	THERAPEUTIC ANTIBODY FORMULATIONS
US20240254217A1 (en)	2021-05-28	2024-08-01	Eli Lilly And Company	Anti -il-23p19 antibody regulation of genes involved in ulcerative colitis
CN113698480B (en) *	2021-09-18	2022-07-01	东大生物技术(苏州)有限公司	Group of IL-23 monoclonal antibodies and medical application thereof
US20240391994A1 (en)	2021-09-30	2024-11-28	Eli Lilly And Company	Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
WO2024077113A1 (en)	2022-10-06	2024-04-11	Eli Lilly And Company	Methods of treating fatigue in ulcerative colitis
CN120882881A (en)	2023-02-22	2025-10-31	伊莱利利公司	Gene regulation of ulcerative colitis and use thereof
AU2024236477A1 (en)	2023-03-10	2025-09-11	Eli Lilly And Company	Methods of treating ulcerative colitis
WO2025083549A1 (en)	2023-10-16	2025-04-24	Sun Pharma Advanced Research Company Limited	Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
WO2025117506A1 (en)	2023-11-29	2025-06-05	Gilead Sciences, Inc.	Therapies for the treatment of inflammatory bowel disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6060284A (en)	1997-07-25	2000-05-09	Schering Corporation	DNA encoding interleukin-B30
US7090847B1 (en)	1999-09-09	2006-08-15	Schering Corporation	Mammalian cytokines; related reagents and methods
US7422743B2 (en)	2000-05-10	2008-09-09	Schering Corporation	Mammalian receptor protein DCRS5;methods of treatment
US7282204B2 (en)	2003-03-10	2007-10-16	Schering Corporation	Uses of IL-23 agonists and antagonists; related reagents
US8003108B2 (en) *	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
SI2452694T1 (en)	2005-06-30	2019-05-31	Janssen Biotech, Inc.	Anti-IL-23 antibodies, compositions, methods and uses
CN101248088A (en) *	2005-08-25	2008-08-20	伊莱利利公司	Anit-il-23 antibiodies
DK1937721T3 (en) *	2005-08-25	2010-10-18	Lilly Co Eli	Anti-IL-23 antibodies
LT1931710T (en) *	2005-08-31	2017-03-27	Merck Sharp & Dohme Corp.	Engineered anti-il-23 antibodies
LT2548577T (en) *	2005-12-29	2017-04-10	Janssen Biotech, Inc.	Human anti-il-23 antibodies, compositions, methods and uses
MX2009009080A (en) *	2007-02-23	2009-11-02	Schering Corp	Engineered anti-il-23p19 antibodies.
LT2426144T (en)	2007-02-23	2018-12-10	Merck Sharp & Dohme Corp.	Engineered anti-il-23p19 antibodies
SI2131860T1 (en) *	2007-03-20	2014-02-28	Eli Lilly And Company	Anti-sclerostin antibodies
WO2008141044A2 (en)	2007-05-08	2008-11-20	Genentech, Inc.	Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2009082624A2 (en) *	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2435480A1 (en) *	2009-05-27	2012-04-04	Ablynx N.V.	Biparatopic protein constructs directed against il-23
ES2593754T3 (en) *	2010-11-04	2016-12-13	Boehringer Ingelheim International Gmbh	Anti-IL-23 antibodies
CA2833212C (en) *	2011-05-12	2020-06-09	Genentech, Inc.	Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides

2014
- 2014-02-25 AR ARP140100582A patent/AR094877A1/en active IP Right Grant
- 2014-02-25 TW TW103106335A patent/TWI636063B/en active
- 2014-02-25 JO JOP/2014/0049A patent/JOP20140049B1/en active
- 2014-03-04 EA EA201591368A patent/EA031524B1/en not_active IP Right Cessation
- 2014-03-04 KR KR1020177024414A patent/KR20170103037A/en not_active Ceased
- 2014-03-04 MA MA38382A patent/MA38382A1/en unknown
- 2014-03-04 PL PL14761062T patent/PL2964258T3/en unknown
- 2014-03-04 MX MX2015011959A patent/MX370396B/en active IP Right Grant
- 2014-03-04 EP EP14761062.0A patent/EP2964258B1/en active Active
- 2014-03-04 SG SG11201507176VA patent/SG11201507176VA/en unknown
- 2014-03-04 JP JP2015561515A patent/JP6096938B2/en active Active
- 2014-03-04 RS RS20201236A patent/RS60928B1/en unknown
- 2014-03-04 AP AP2015008708A patent/AP2015008708A0/en unknown
- 2014-03-04 DK DK14761062.0T patent/DK2964258T3/en active
- 2014-03-04 EP EP20193400.7A patent/EP3789037A1/en not_active Withdrawn
- 2014-03-04 PT PT147610620T patent/PT2964258T/en unknown
- 2014-03-04 US US14/195,889 patent/US9023358B2/en active Active
- 2014-03-04 KR KR1020157024032A patent/KR101775115B1/en active Active
- 2014-03-04 WO PCT/US2014/020064 patent/WO2014137962A1/en not_active Ceased
- 2014-03-04 LT LTEP14761062.0T patent/LT2964258T/en unknown
- 2014-03-04 CN CN201480012747.7A patent/CN105307681B/en active Active
- 2014-03-04 AU AU2014226094A patent/AU2014226094C1/en active Active
- 2014-03-04 HR HRP20201633TT patent/HRP20201633T1/en unknown
- 2014-03-04 HU HUE14761062A patent/HUE051357T2/en unknown
- 2014-03-04 SI SI201431653T patent/SI2964258T1/en unknown
- 2014-03-04 CA CA2901462A patent/CA2901462C/en active Active
- 2014-03-04 BR BR112015019611-0A patent/BR112015019611B1/en active IP Right Grant
- 2014-03-04 EP EP23207282.7A patent/EP4311558A3/en active Pending
- 2014-03-04 MY MYPI2015702927A patent/MY171226A/en unknown
- 2014-03-04 ES ES14761062T patent/ES2822662T3/en active Active
- 2014-03-04 PH PH1/2015/501994A patent/PH12015501994B1/en unknown
- 2014-03-04 PE PE2015001903A patent/PE20151529A1/en active IP Right Grant
- 2014-03-04 UA UAA201508670A patent/UA123198C2/en unknown
2015
- 2015-05-01 US US14/702,124 patent/US9688753B2/en active Active
- 2015-07-22 ZA ZA2015/05285A patent/ZA201505285B/en unknown
- 2015-08-12 TN TN2015000348A patent/TN2015000348A1/en unknown
- 2015-08-20 IL IL240731A patent/IL240731B/en active IP Right Grant
- 2015-08-26 CL CL2015002388A patent/CL2015002388A1/en unknown
- 2015-09-08 EC ECIEPI201538626A patent/ECSP15038626A/en unknown
2017
- 2017-06-01 US US15/611,008 patent/US20170275356A1/en not_active Abandoned
2020
- 2020-01-14 IL IL272042A patent/IL272042B/en unknown
- 2020-11-16 CY CY20201101081T patent/CY1123589T1/en unknown
2023
- 2023-10-03 FI FIC20230030C patent/FIC20230030I1/en unknown
- 2023-10-04 NO NO2023037C patent/NO2023037I1/en unknown
- 2023-10-06 NL NL301247C patent/NL301247I2/en unknown
- 2023-10-06 CY CY2023021C patent/CY2023021I2/en unknown
- 2023-10-13 FR FR23C1036C patent/FR23C1036I2/en active Active
- 2023-10-18 HU HUS2300036C patent/HUS2300036I1/en unknown
- 2023-10-23 LT LTPA2023530C patent/LTC2964258I2/lt unknown

Also Published As

Publication number	Publication date
EP4311558A3 (en)	2024-04-10
PE20151529A1 (en)	2015-10-28
PH12015501994B1 (en)	2023-03-01
JP6096938B2 (en)	2017-03-15
HRP20201633T1 (en)	2020-12-25
MA38382A1 (en)	2017-11-30
PH12015501994A1 (en)	2016-01-11
FR23C1036I1 (en)	2023-12-08
AU2014226094B2 (en)	2016-06-23
TWI636063B (en)	2018-09-21
TN2015000348A1 (en)	2017-01-03
IL272042A (en)	2020-02-27
AP2015008708A0 (en)	2015-09-30
SI2964258T1 (en)	2020-10-30
US20150232552A1 (en)	2015-08-20
TW201520225A (en)	2015-06-01
BR112015019611B1 (en)	2023-05-02
ZA201505285B (en)	2017-11-29
UA123198C2 (en)	2021-03-03
NL301247I1 (en)	2023-10-11
HK1212252A1 (en)	2016-06-10
HUS2300036I1 (en)	2024-07-28
IL272042B (en)	2021-07-29
US9688753B2 (en)	2017-06-27
DK2964258T3 (en)	2020-09-14
LTPA2023530I1 (en)	2023-11-10
KR20150113202A (en)	2015-10-07
IL240731B (en)	2020-01-30
CN105307681A (en)	2016-02-03
NO2023037I1 (en)	2023-10-04
SG11201507176VA (en)	2015-10-29
AU2014226094A1 (en)	2015-08-27
JP2016510744A (en)	2016-04-11
RS60928B1 (en)	2020-11-30
CA2901462C (en)	2017-07-25
NL301247I2 (en)	2023-11-01
WO2014137962A1 (en)	2014-09-12
CY1123589T1 (en)	2022-03-24
CY2023021I2 (en)	2024-09-20
LT2964258T (en)	2020-10-12
IL240731A0 (en)	2015-10-29
EP4311558A2 (en)	2024-01-31
AR094877A1 (en)	2015-09-02
HUE051357T2 (en)	2021-03-01
US20140255422A1 (en)	2014-09-11
MX370396B (en)	2019-12-11
FIC20230030I1 (en)	2023-10-03
EP3789037A1 (en)	2021-03-10
LTC2964258I2 (en)	2025-09-10
MX2015011959A (en)	2016-04-07
CY2023021I1 (en)	2024-02-16
KR101775115B1 (en)	2017-09-05
US9023358B2 (en)	2015-05-05
EP2964258B1 (en)	2020-09-02
CN105307681B (en)	2018-06-26
ECSP15038626A (en)	2015-11-30
EP2964258A4 (en)	2016-10-12
US20170275356A1 (en)	2017-09-28
EA201591368A1 (en)	2015-12-30
AU2014226094C1 (en)	2024-10-24
PL2964258T3 (en)	2021-02-08
BR112015019611A2 (en)	2017-08-22
MY171226A (en)	2019-10-03
NZ711147A (en)	2021-03-26
EA031524B1 (en)	2019-01-31
CA2901462A1 (en)	2014-09-12
JOP20140049B1 (en)	2021-08-17
PT2964258T (en)	2020-11-06
CL2015002388A1 (en)	2016-03-04
ES2822662T3 (en)	2021-05-04
EP2964258A1 (en)	2016-01-13
KR20170103037A (en)	2017-09-12

Publication	Publication Date	Title
FR23C1036I2 (en)	2024-10-04	ANTIBODIES THAT BIND TO IL-23
FR25C1038I1 (en)	2025-11-21	ANTI-TROP2-MEDICINE ANTIBODY CONJUGATE
DK3049441T3 (en)	2020-02-03	Anti-PDL1 antibody formulations
DK3336106T3 (en)	2020-07-13	ANTI-FCRH5 ANTIBODIES
EP3334757A4 (en)	2019-04-03	ANTI-TIGIT ANTIBODIES
IL267382A (en)	2019-08-29	Proteins that bind antigen to the oncostatin receptor
EP2970505A4 (en)	2016-10-19	BISPECIFIC ANTIBODIES AND USES THEREOF
EP3297671A4 (en)	2019-02-06	ANTI-ROR1 ANTIBODIES
ME03675B (en)	2020-10-20	HUMANIZED OR CHIMERAL ANTI-CD3 ANTIBODIES
HUE051496T2 (en)	2021-03-01	Antibodies that specifically bind to TL1A
MA45004A (en)	2019-03-27	ANTI-WT1-HLA SPECIFIC ANTIBODIES
DK3708583T3 (en)	2022-05-16	NON-FUCOSYLED ANTI-FGFR2IIIB ANTIBODIES
EP2968553A4 (en)	2016-10-19	ANTIBODY FORMULATIONS
EP2981286A4 (en)	2016-08-24	ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF
FR3014362B1 (en)	2017-03-17	PERFECTIONED ROLLING ASSEMBLY
DK3068800T3 (en)	2019-10-21	FcRn-specific antibodies
EP2948981A4 (en)	2016-03-23	THERMOELECTRIC ASSEMBLY
MA42843A (en)	2018-07-25	ANTI-CD115 ANTIBODY
EP3381941A4 (en)	2019-05-01	ANTI-EPHA4 ANTIBODIES
EP3336185A4 (en)	2019-01-16	ANTIBODY
EP3336184A4 (en)	2019-01-23	ANTIBODY
DK3065774T3 (en)	2021-08-23	Anti-CCL17 antibodies
EP2830663A4 (en)	2016-07-27	COMPLETELY HUMAN ANTIBODIES THAT BIND TO VEGFR2
EP2970503A4 (en)	2016-11-30	MONOCLONAL ANTIBODIES ANTI - (+) - METHAMPHETAMINE
FR3002228B1 (en)	2016-02-19	MONOCLONAL ANTIBODIES AND USES